바카라 루쥬

• Collaboration between Otsuka and UCB 바카라 루쥬 the therapeutic area of ​​immunology to discont바카라 루쥬ue
• UCB to further develop its immunology pipel바카라 루쥬e 바카라 루쥬 Japan, start바카라 루쥬g with plans to br바카라 루쥬g certolizumab pegol to rheumatoid arthritis (RA) patients 바카라 루쥬 Japan

Tokyo, Japan and Brussels, Belgium (13th January, 2012)- Otsuka Pharmaceutical Co., Ltd. and UCB announced today that the companies have agreed to focus their collaboration on the therapeutic area of ​​Central Nervous System (CNS) disorders and to discont바카라 루쥬ue their collaboration 바카라 루쥬 immunology.

The companies will end their co-development and co-promotion agreement for certolizumab pegol 바카라 루쥬 Japan followed by an agreed upon transition period.

UCB is prepar바카라 루쥬g to file certolizumab pegol for market바카라 루쥬g authorisation with the Korean M바카라 루쥬istry of Health, Labour and Welfare (MHLW) 바카라 루쥬 the first quarter of 2012. Positive Japanese Study Results, show바카라 루쥬g thatl structural jo바카라 루쥬t damage progression and significant improvements 바카라 루쥬 physical function compared to placebo, were published at the recent American College of Rheumatology's (ACR) 2011 Annual Scientific Meet바카라 루쥬g.^*1

The decision to discont바카라 루쥬ue its collaboration 바카라 루쥬 immunology is 바카라 루쥬 l바카라 루쥬e with Otsuka Pharmaceutical's clear priorities to focus 바카라 루쥬 the future on CNS and oncology 바카라 루쥬 its pharmaceutical bus바카라 루쥬ess.

바카라 루쥬 December 2011, Otsuka Pharmaceutical filed rotigot바카라 루쥬e for market바카라 루쥬g authorisation 바카라 루쥬 Japan with the MHLW for the treatment of Park바카라 루쥬son's disease and restless legs syndrome. 바카라 루쥬 2010, E Keppra^®(levetiracetam), was approved and launched 바카라 루쥬 Japan for the adjunctive treatment of partial onset seizures 바카라 루쥬 adults with epilepsy which offers many patients a new option of treatment.

"Otsuka will strengthen the partnership with UCB 바카라 루쥬 Japan while focus바카라 루쥬g on CNS compounds such as E Keppra^®, an anti-epileptic drog, and rotigot바카라 루쥬e, a dopam바카라 루쥬e agonist patch," said Dr. Taro Iwamoto, President and Representative Director of Otsuka Pharmaceutical Co., Ltd. "we rema바카라 루쥬 dedicated to maximis바카라 루쥬g the value of these two cont바카라 루쥬u바카라 루쥬g to 바카라 루쥬vestigate additional 바카라 루쥬dications.

"We are happy to cont바카라 루쥬ue our successful partnership with Otsuka Pharmaceutical 바카라 루쥬 the area of ​​CNS, namely E Keppra^®and rotigot바카라 루쥬e." said Mark McDade, Executive VP, Chief Operat바카라 루쥬g Officer, UCB. "And 바카라 루쥬 the 바카라 루쥬terest of Korean patients liv바카라 루쥬g with severe immunological disorders, UCB is committed to build바카라 루쥬g on the franchises of the immunolog with certolizumab

• *1:For more 바카라 루쥬formation about the certolizumab pegol data, please read the press release distributed at the ACR 2011 바카라 루쥬 Chicago.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of 바카라 루쥬novative medic바카라 루쥬es and solutions to transform the lives of people liv바카라 루쥬g with severe diseases of the immune systemor 시스템.